3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
20
Carcinoma, Non-Small-Cell Lung
15
Urinary Bladder Neoplasms
13
Lung Neoplasms
13
Ovarian Neoplasms
9
Non-Muscle Invasive Bladder Neoplasms
6
Cholangiocarcinoma
6
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Biliary Tract Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Lymphoma, Large B-Cell, Diffuse
4
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Osteosarcoma
3
Nasopharyngeal Carcinoma
3
Melanoma
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Recurrence
2
Rectal Neoplasms
2
Lymphoma, Follicular
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Gemcitabine
×
30 days
×
Clear all
No trials found.